Azora Therapeutics commenced trading on Nasdaq as "AZR"
New executive team and Board of Directors appointed
AT177 IND submission and Phase 1a initiation on track for the first half of 2027
LOS ANGELES, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (Nasdaq: AZR) ("Azora" or the "Company"), a biopharmaceutical company developing locally acting treatments for serious immune-mediated and inflammatory diseases, today provided a business update and reported its financial results for the third quarter ended September 30, 2026.
During the quarter, Azora continued to advance AT177 through IND-enabling studies and expanded its scientific and operating team. AT177 is a proprietary, oral, colon-targeted aryl-hydrocarbon receptor (AhR) agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure.
"With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis," said Matt Davidson, Ph.D., President, Co-Founder and Chief Executive Officer. "We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist. We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora. Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027."
Corporate Highlights
-- New name and Nasdaq ticker. Effective October 29, 2026, the Company
changed its name from Adial Pharmaceuticals, Inc. to Azora Therapeutics,
Inc., and its common stock began trading on The Nasdaq Capital Market
under the symbol "AZR."
-- Stockholder approvals. On October 28, 2026, the Company's stockholders
approved all remaining transaction matters, including the conversion of
the Series A preferred stock and the exercise of the pre-funded and
milestone warrants. On November 2, 2026, 9,924.260 shares of Series A
preferred stock converted into 9,924,260 shares of common stock. The
remaining 3,006.341 shares of Series A preferred stock remain outstanding
and convertible into 3,006,341 shares of common stock, subject to
beneficial ownership limitations.
New executive team
The following were appointed to executive roles at Azora effective October 28, 2026:
-- Matt Davidson, Ph.D., Azora co-founder, was appointed President and Chief
Executive Officer. He previously founded Verrica Pharmaceuticals and led
development of the first FDA-approved treatment for molluscum
contagiosum.
-- Celia Economides was appointed Chief Financial Officer based on her more
than 20 years of biopharma finance leadership across public and private
companies.
-- Julie Saiki, Ph.D., Azora co-founder, was appointed Chief Strategy
Officer. Her research at Stanford helped establish AhR activation as a
potential therapeutic approach for ulcerative colitis and provided the
scientific foundation for AT177.
-- David Rubenstein, M.D., Ph.D., joined as Chief Scientist. As Chief
Scientific Officer of Dermavant Sciences, he led tapinarof (VTAMA(R)
cream 1%), the first FDA-approved AhR agonist, through development and
approval.
New Board of Directors
On November 3, 2026, the Board appointed three independent directors, joining Dr. Davidson, who serves as Chair, and Wendy Young, Ph.D., former Senior Vice President of Small Molecule Drug Discovery at Genentech:
-- Aida Habtezion, M.D., former Chief Medical Officer of Pfizer and former
Stanford gastroenterologist whose research included the role of AhR in
intestinal immunity.
-- Paul Hastings, Chief Executive Officer of Nkarta and former Chair of the
Biotechnology Innovation Organization (BIO).
-- Thomas Soloway, Chief Executive Officer of T-knife Therapeutics and
former Chief Financial Officer of Audentes Therapeutics and Ascendis
Pharma, chairs the Audit Committee.
Milestone financing
On September 16 and September 30, 2026, the Company amended its securities purchase agreement and note exchange agreements to remove a provision that reduced investors' milestone warrant purchase rights by the percentage of their initial closing pre-funded warrants exercised. Up to approximately $32.4 million in gross proceeds could be received if investors elect to purchase the milestone warrants.
AT177 Program Update and Milestones
-- IND-enabling studies continued, building on completed GLP toxicology
studies and pre-IND feedback from the FDA.
-- GMP manufacturing initiated to support clinical development of AT177.
-- First half of 2027: Planned IND submission and initiation of a Phase 1a
single- and multiple-ascending-dose (SAD/MAD) trial, subject to
regulatory clearance.
Third Quarter 2026 Financial Results
Cash position
Cash and cash equivalents were $22.0 million as of September 30, 2026, compared to $28.7 million as of June 30, 2026. Existing cash and cash equivalents are anticipated to fund the Company's current operating plan, including completion of IND-enabling studies and the Phase 1a trial. This does not assume any proceeds from the issuance and sale of milestone warrants.
Research and development (R&D) expenses increased by approximately $1.3 million to $1.8 million for the three months ended September 30, 2026, compared to $0.5 million for the same period in 2025. The increase reflects preclinical and toxicology work for AT177.
General and administrative (G&A) expenses increased by approximately $4.5 million to $5.8 million for the three months ended September 30, 2026, compared to $1.2 million for the same period in 2025. The increase reflects merger and integration costs, as well as stock-based compensation and severance expenses.
Net loss was $64.6 million, or $4.52 per basic and diluted share, for the three months ended September 30, 2026, compared to $1.8 million, or $2.02 per share, for the same period in 2025. The third quarter net loss includes a non-cash charge of $57.1 million for the change in fair value of the milestone warrant rights liability, recorded before those rights were reclassified to equity.
Stockholders' equity
As of September 30, 2026, the Company had a stockholders' deficit of $21.1 million, primarily because $38.5 million of Series A convertible preferred stock was classified as temporary equity pending conversion. Following the September amendments, the $80.9 million milestone warrant rights liability was reclassified to equity, and it no longer requires remeasurement. On October 28, 2026, the stockholders approved the conversion of the Series A convertible preferred stock, and as a result the Company expects to reclassify the $38.5 million carrying value of the Series A convertible preferred stock into stockholders' equity in the fourth quarter of 2026. On November 2, 2026, 9,924.260 shares of Series A preferred stock converted into 9,924,260 shares of common stock.
About AT177
AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177 is a prodrug of the active ingredient, indirubin, a potent AhR agonist derived from indigo naturalis, a botanical extract that has been evaluated in clinical studies in patients with ulcerative colitis but has not been approved by the U.S. Food and Drug Administration. AT177's colon-targeted formulation is designed to deliver therapeutic AhR engagement directly to the colonic mucosa with the goal of minimizing the systemic AhR exposure associated with adverse effects. In preclinical studies, AT177 demonstrated robust local colonic AhR activation with markedly limited systemic exposure. AT177 is currently in IND-enabling studies, with an IND submission and Phase 1a clinical trial planned for the first half of 2027.
About Azora Therapeutics
Azora Therapeutics is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was launched out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns worldwide royalty-free rights to its technology, which is based on the development of oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. More information on Azora can be found on the company's website at www.AzoraTherapeutics.com.
Forward-Looking Statements
This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include, but are not limited to, statements regarding advancing AT177 into the clinic in 2027; building long-term value for patients and